➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
AstraZeneca
Dow
Mallinckrodt
Merck

Last Updated: October 21, 2021

DrugPatentWatch Database Preview

Litigation Details for AstraZeneca Pharmaceuticals LP v. Teva Pharmaceuticals USA Inc. (D. Del. 2014)


Email this page to a colleague

« Back to Dashboard

Small Molecule Drugs cited in AstraZeneca Pharmaceuticals LP v. Teva Pharmaceuticals USA Inc.
The small molecule drugs covered by the patents cited in this case are ⤷  Try it Free , ⤷  Try it Free , ⤷  Try it Free , and ⤷  Try it Free .

Details for AstraZeneca Pharmaceuticals LP v. Teva Pharmaceuticals USA Inc. (D. Del. 2014)

Date Filed Document No. Description Snippet Link To Document
2014-12-11 1 Complaint expiration of U.S. Patent Nos. 6,858,576 (the “’576 patent”), 6,872,700 (the “’700 patent”), 6,956,026 (the…Paragraph IV Certification Concerning U.S. Patent Nos. 6,858,576, 6,872,700, 6,902,744, 6,956,026, 7,297,761…of the ’576 patent, the ’700 patent, the ’026 patent, the ’744 patent, and the ’423 patent (collectively…(the “’026 patent”), 7,297,761 (the “’761 patent”), 6,902,744 (the “’744 patent”), 7,521,423 (the “’423… This action is for patent infringement, brought pursuant to the patent laws of the United States External link to document
2015-02-08 16 Answer to Counterclaim United States Patent No. 6,858,576 19. Plaintiffs repeat and… United States Patent No. 6,858,576 39. Plaintiffs repeat and…744 patent and at times to the ’423 patent. To the extent paragraph 57 refers to the ’744 patent, Plaintiffs…744 patent and at times to the ’423 patent. To the extent paragraph 58 refers to the ’744 patent, Plaintiffs…the ’576, ’700, ’026, ’744 and ’423 patents and two other patents. Plaintiffs further admit that Teva External link to document
2014-12-11 4 Patent/Trademark Report to Commissioner the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,858,576; 6,872,700; 6,956,026…2014 27 June 2016 1:14-cv-01478 830 Patent None District Court, D. Delaware External link to document
2015-06-08 41 Notice of Service Identification of Asserted Claims of U.S. Patent Nos. 7,297,761 & 7,741,269 filed by Amylin Pharmaceuticals…2014 27 June 2016 1:14-cv-01478 830 Patent None District Court, D. Delaware External link to document
2015-06-29 43 SO ORDERED serve its invalidity contentions as to U.S. Patent Nos. 6,858,576; 6,872,700; 6,956,026; 7,741,269…non- infringement contentions as to U.S. Patent Nos. 7,297,761 and 7,741,269 is extended to … to serve its infringement contentions for U.S. Patent Nos. 7,297,761 and 7,741,269 is extended…2014 27 June 2016 1:14-cv-01478 830 Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Mallinckrodt
McKinsey
Medtronic
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.